Issue 126 • January 2023 Expanding ketamine’s horizons for rare neurological disorders The “Medical Bypass”: New drugs to strike obesity ACT EU state of play: EMA’s headway to transform clinical trials In association with Humira biosimilars set the stage for long-awaited 2023 US launches After much buzz, the entry of Humira biosimilars is being seen as a major cost-cutting opportunity, but market penetration will not be instant In association with Issue 126 Brought to you by 12/15/2022 09:27:35